Designing better care- Our purpose is to design care experiences that get the best possible life outcomes. Our goal is to deliver exceptional treatment and care in a way that enhances every aspect of your cancer journey.
“We [at GenesisCare] would be really interested in looking at strategies to identify men that we think are aggressive but localized and offer them a chance to do a shorter course hormonal therapy, which is going to substantially improve quality of life without losing on the efficacy end,” says Bridget F. Koontz, MD.
“The RTOG-0815 study [of dose-escalated RT plus androgen suppression] has provided...data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.
The oncology provider will enable patient access to the PSMA-PET imaging agent piflufolastat F 18, which the FDA approved in May 2021 for identifying suspected metastasis or recurrence of prostate cancer.